雄性激素剝奪療法 (ADT) 市場規模、佔有率和成長分析（按 ADT 類型、適應症、給藥途徑、患者人群、通路和地區分類）— 2026-2033 年行業預測

全球雄性激素剝奪療法市場規模預計在 2024 年達到 70.8 億美元，從 2025 年的 74.7 億美元成長到 2033 年的 115.5 億美元，在預測期（2026-2033 年）內複合年成長率為 5.6%。

由於前列腺癌發生率上升以及人們對荷爾蒙敏感性腫瘤的認知不斷提高，全球雄性激素剝奪療法市場正經歷顯著成長。藥物遞送技術的創新，包括長效注射劑和口服療法，正在擴大治療選擇。除了人口老化帶來的診斷率提高外，有利的報銷政策和數位化監測解決方案也改善了患者獲得治療的機會。然而，潛在的心血管副作用以及開發中國家的高成本等挑戰仍然是該療法廣泛應用的障礙。未來市場趨勢，包括基於人工智慧的治療最佳化、生物類似藥的興起以及即時荷爾蒙抑制監測技術的進步，預計將對長期臨床療效和市場潛力產生影響。

全球雄性激素剝奪療法市場促進因素

全球老年男性前列腺癌發生率的不斷上升是推動雄性激素剝奪療法需求成長的主要因素。雄性激素剝奪療法仍是荷爾蒙敏感性前列腺癌（尤其是進行性或轉移性病例）的主要治療選擇。此外，政府加強篩檢政策以及人們對早期發現重要性的認知不斷提高，也促進了治療量的成長。這些因素共同凸顯了雄性激素剝奪療法在前列腺癌治療中的重要作用，因為醫療保健系統正在努力滿足這群患者對有效干預措施日益成長的需求。因此，預計該療法的市場將迎來顯著成長。

全球雄性激素剝奪療法市場的限制因素

全球雄性激素剝奪療法市場的發展受到治療成本高昂的嚴重限制，尤其是新型口服抑制劑和長效注射劑的成本。這些費用往往超出開發中國家的標準保險覆蓋範圍和公共醫療預算，造成沉重的經濟負擔。此外，病患報銷不足以及醫療體系的脫節進一步加劇了這個問題。因此，經濟負擔使得許多需要治療的患者無法獲得這些療法，最終限制了市場整體成長及其在服務不足地區的覆蓋範圍。

全球雄性激素剝奪療法市場趨勢

全球雄性激素剝奪療法市場正經歷著向新一代口服荷爾蒙阻斷劑的顯著轉變，其主要驅動力在於藥物的便利性和減少就診次數。這一趨勢反映出前列腺癌治療中，人們越來越傾向於採用分散式治療方法，口服促性腺激素釋放激素（LHRH）拮抗劑和抗雄性激素藥物正逐漸成為第一線治療方案。患者擴大選擇口服療法而非傳統的注射療法，因為口服療法具有更大的治療柔軟性和更高的依從性。這些創新治療方法的普及正在重塑市場格局，並凸顯出醫療保健系統中雄性激素剝奪療法的實施和認知方式的模式轉移。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

全球雄性激素剝奪療法 (ADT) 市場規模（按 ADT 類型和複合年成長率分類）（2026-2033 年）

• GnRH類似物
• 抗雄激素

全球雄性激素剝奪療法 (ADT) 市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 局限性前列腺癌
• 進行性前列腺癌

全球雄性激素剝奪療法 (ADT) 市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 肌肉內注射
• 皮下注射

全球雄性激素剝奪療法 (ADT) 市場規模（按患者群體分類）及複合年成長率 (2026-2033)

• 40至60歲的男性
• 61至75歲的男性
• 75歲及以上的男性

全球雄性素剝奪療法 (ADT) 市場規模（按分銷管道分類）及複合年成長率 (2026-2033)

• 醫院
• 專科癌症診所
• 網路藥房
• 零售藥房

全球雄性激素剝奪療法（ADT）市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Ferring BV
• AstraZeneca
• Bayer AG
• Astellas Pharma Inc
• Johnson & Johnson
• Foresee Pharmaceuticals Co Ltd
• Viatris
• Verity Pharmaceuticals Inc
• AbbVie Inc
• Bristol-Myers Squibb Company
• Tolmar Pharmaceuticals Inc

結論與建議

Global Androgen Deprivation Therapy Market size was valued at USD 7.08 Billion in 2024 and is poised to grow from USD 7.47 Billion in 2025 to USD 11.55 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).

The global market for androgen deprivation therapy is experiencing significant growth due to the rising incidence of prostate cancer and heightened awareness regarding hormone-sensitive tumors. Innovations in drug delivery, including long-acting injectables and oral therapies, are enhancing treatment options. Increased diagnosis rates among aging populations, alongside favorable reimbursement policies and digital monitoring solutions, are improving patient access to therapy. Nonetheless, challenges such as potential cardiac side effects and high costs in developing nations pose barriers to widespread adoption. Future trends shaping the market include AI-driven therapy optimization, the emergence of biosimilars, and advanced methods for real-time hormone suppression monitoring, all of which are poised to impact long-term clinical outcomes and market viability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Androgen Deprivation Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Androgen Deprivation Therapy Market Segments Analysis

Global Androgen Deprivation Therapy Market is segmented by Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Type of ADT, the market is segmented into GnRH Analogues and Anti-androgens. Based on Indication, the market is segmented into Localized Prostate Cancer and Advanced Prostate Cancer. Based on Route of Administration, the market is segmented into Intramuscular and Subcutaneous. Based on Patient Demographics, the market is segmented into Men aged 40-60, Men aged 61-75 and Men above 75. Based on Distribution Channel, the market is segmented into Hospitals, Specialized Cancer Clinics, Online Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Androgen Deprivation Therapy Market

The increasing global prevalence of prostate cancer among older males is significantly driving the demand for androgen deprivation therapy, which remains the primary treatment choice for hormone-sensitive prostate cancer, particularly in advanced or metastatic cases. Additionally, enhanced government screening initiatives and a growing awareness surrounding the importance of early detection are contributing to higher treatment volumes. This combination of factors underscores the critical role of androgen deprivation therapy in managing prostate cancer, as healthcare systems respond to the rising need for effective interventions in this patient population. Consequently, the market for this therapy is expected to see substantial growth.

Restraints in the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market is significantly hindered by the high costs associated with treatments, especially those involving newer oral blockers and long-acting injectables. These expenses often exceed the limits of standard insurance coverage or the allocation of public health budgets in developing nations, creating a major affordability challenge. Additionally, inadequate reimbursement options for patients, combined with poorly coordinated healthcare systems, further exacerbate this issue. As a result, the financial burden restricts access to these therapies for many individuals who need them, ultimately limiting the overall market growth and potential reach in underserved regions.

Market Trends of the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market is experiencing a significant shift towards new-generation oral hormone blockers, driven by their convenience and reduced need for frequent clinic visits. This trend represents a growing preference for decentralized treatment options in prostate cancer management, as oral LHRH antagonists and antiandrogens transition into first-line therapies. Patients are increasingly opting for oral-only therapies over traditional injectable treatments, enhancing treatment flexibility and adherence. The proliferation of these innovative therapies is reshaping the market landscape, highlighting a paradigm shift in how androgen deprivation therapy is administered and perceived within the healthcare ecosystem.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Androgen Deprivation Therapy Market Size by Type of ADT & CAGR (2026-2033)

• Market Overview
• GnRH Analogues
• Anti-androgens

Global Androgen Deprivation Therapy Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Localized Prostate Cancer
• Advanced Prostate Cancer

Global Androgen Deprivation Therapy Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intramuscular
• Subcutaneous

Global Androgen Deprivation Therapy Market Size by Patient Demographics & CAGR (2026-2033)

• Market Overview
• Men aged 40-60
• Men aged 61-75
• Men above 75

Global Androgen Deprivation Therapy Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialized Cancer Clinics
• Online Pharmacies
• Retail Pharmacies

Global Androgen Deprivation Therapy Market Size & CAGR (2026-2033)

• North America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • US
  • Canada
• Europe (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Ferring B V
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foresee Pharmaceuticals Co Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Verity Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tolmar Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations